TrialJournal of Korean medical science2007

A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.

Dong Hoe Koo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.